GlaxoSmithKline Plc on Monday presented new data on the benefits of its ReQuip drug in treating restless leg syndrome, which the company hopes will strengthen its case for marketing approval.
Results of a GSK-sponsored analysis of four clinical trials, presented at the annual meeting of the European Federation of Neurological Societies in Paris, showed patients enjoyed more and better quality sleep as early as one week after starting treatment. ReQuip is an established treatment for Parkinson's disease that Europe's biggest drug maker believes can also help patients with the common neurological disorder, which is a leading cause of insomnia. People with restless leg syndrome (RLS) have an uncontrollable urge to move the legs and often experience painful or unpleasant sensations in the lower limbs. In January, U.S. regulators told GSK they wanted more information about ReQuip before approving it for use as a treatment of the condition. If finally approved, ReQuip would be the first medicine with U.S. clearance for treating RLS.